Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial

[2][3] The doxazosin arm was discontinued early on in the trial because of a higher rate of combined cardiovascular events and admissions for heart failure compared with chlorthalidone.

The study also confirmed the previously held views that ACE inhibitors were less effective in blood pressure control and stroke prevention in men of African and Caribbean descent.

In February 1994, initially 42,418 people, age over 55 years, with stage I or II hypertension or who were taking medication for high blood pressure were recruited across 623 centres in Canada, Puerto Rico, the US, and the US Virgin Islands.

All had at least one other CHD risk factor including previous heart attack or stroke, electrocardiogram or echocardiogram verified left ventricular hypertrophy (LVH), a history of type II diabetes mellitus, current cigarette smoking, and low high-density lipoprotein cholesterol levels.

The study confirmed the previously held views that ACE inhibitors were less effective in blood pressure control and stroke prevention in men of African and Caribbean descent.